View Older Stories View More Recent Stories

Jul 9, 2021 01:36PM Biogen (BIIB) Shares Down 4% As Head of FDA Calls for a Federal Investigation into Approval of Aduhelm
Jul 8, 2021 04:06PM Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Jul 8, 2021 04:06PM Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Jul 8, 2021 07:31AM Biogen (BIIB) Announces FDA Approves Updated ADUHELM Prescribing Information to Emphasize Population Studied in Clinical Trials
Jul 8, 2021 07:30AM FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
Jul 8, 2021 07:30AM FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
Jun 25, 2021 07:31AM Samsung Bioepis and Biogen (BIIB) Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ
Jun 25, 2021 07:30AM Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
Jun 25, 2021 07:30AM Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
Jun 23, 2021 04:07PM Eisai, Biogen (BIIB) Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 23, 2021 04:06PM Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 17, 2021 07:30AM Biogen (BIIB) Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Jun 17, 2021 07:30AM Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Jun 17, 2021 07:30AM Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Jun 16, 2021 04:31PM Biogen (BIIB) Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Jun 16, 2021 04:30PM Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Jun 16, 2021 04:30PM Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Jun 15, 2021 06:32AM Sage Therapeutics (SAGE), Biogen (BIIB) Phase 3 for Zuranolone for Major Depressive Disorder Shows Statistically Significant Improvement
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Jun 15, 2021 06:30AM Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Jun 14, 2021 04:07PM Biogen (BIIB) Phase 3 Gene Therapy Study in Choroideremia Did Not Meet its Primary Endpoint
Jun 14, 2021 04:06PM Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
Jun 14, 2021 04:06PM Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
Jun 10, 2021 04:06PM Biogen Announces Investor Day on September 21, 2021
Jun 10, 2021 04:06PM Biogen Announces Investor Day on September 21, 2021
Jun 10, 2021 07:35AM Biogen (BIIB) Says New Data at Cure SMA 2021 Highlight Long-Term Efficacy of SPINRAZA and its Commitment to Innovation in SMA Therapy
Jun 10, 2021 07:30AM New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
Jun 10, 2021 07:30AM New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
Jun 7, 2021 01:01PM Biogen (BIIB) Confirms FDA Accelerated Approval for Alzheimer's Treatment ADUHELM
Jun 7, 2021 01:01PM Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Jun 7, 2021 01:01PM Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Jun 7, 2021 01:00PM FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Jun 7, 2021 01:00PM FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Jun 1, 2021 07:30AM Biogen (BIIB), Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra
Jun 1, 2021 07:30AM Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
Jun 1, 2021 07:30AM Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
May 21, 2021 07:31AM Biogen (BIIB), Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
May 21, 2021 07:30AM Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
May 21, 2021 07:30AM Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
May 20, 2021 04:06PM Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
May 20, 2021 04:06PM Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
May 14, 2021 07:31AM Biogen (BIIB) Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 14, 2021 07:30AM Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 14, 2021 07:30AM Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 13, 2021 04:06PM Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
May 13, 2021 04:06PM Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
May 12, 2021 07:30AM Biogen (BIIB) Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
May 12, 2021 07:30AM Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
May 12, 2021 07:30AM Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
View More Recent Stories View Older Stories